Friday, November 13, 2026

US and China Formalize Parallel AI Chip Supply Chains with Simultaneous Export Controls

Washington banned Nvidia chip exports to China while Beijing approved select H200 chips and accelerated Huawei's 950PR processor development, creating two separate global AI infrastructure ecosystems. Multinational companies must now maintain dual development environments across CUDA and CANN platforms. Investment capital flows toward China-focused AI infrastructure firms that can navigate the bifurcated hardware landscape.

LM Salvado
LM Salvado

March 30, 2026

This article was written by AI. Published before our source requirement (10 August 2026); sources were not recorded. How we work

US and China Formalize Parallel AI Chip Supply Chains with Simultaneous Export Controls
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

The US and China executed coordinated regulatory actions on March 30 that split the global AI chip market into two incompatible supply chains. Washington banned Nvidia chip exports to China while Beijing approved specific H200 chips domestically and fast-tracked Huawei's 950PR processor.1

The dual approval system forces a global infrastructure divide. North American, European, and allied Asian markets standardize on Nvidia's CUDA framework, while China builds around Huawei's CANN platform. This architectural split affects hardware, training frameworks, model optimization, and deployment pipelines worldwide.

Huawei's accelerated 950PR timeline signals China's drive beyond supply chain parity toward independent advanced AI capabilities. The processor targets workloads previously handled by restricted Nvidia chips.1 Chinese tech firms face a choice: develop on domestic hardware with limited international compatibility or maintain separate systems for global markets.

Multinational AI companies across Europe, Asia, and North America must now run duplicate infrastructure. Training a large language model in Shanghai requires different hardware, libraries, and engineering than training in London or Silicon Valley. This duplication raises development costs and complicates cross-border model deployment for global research teams.

The regulatory coordination marks both governments treating AI chip access as essential to technological sovereignty. Previous export controls targeted specific models, enabling workarounds. This approach blocks entire categories while promoting domestic alternatives simultaneously.

Investment capital flows toward China-focused AI infrastructure companies navigating local regulations and hardware constraints. Firms specializing in CANN optimization, Huawei integration, or cross-platform tools represent early beneficiaries of this global split.

The bifurcation creates obstacles for international AI research collaboration. Models trained on one ecosystem transfer inefficiently to another, limiting knowledge sharing between Western and Chinese research institutions and increasing redundant work across the divide.

In this story · Knowledge Files

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com